Latest news

Huntington's disease therapeutics conference 2021 - Day 3

Huntington's disease therapeutics conference 2021 - Day 3

Catch up on all of the latest updates from day 3 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021

Dr Rachel Harding, Dr Leora Fox, and Professor Ed WildApril 29, 2021

Huntington’s disease therapeutics conference 2021 - Day 1

Huntington’s disease therapeutics conference 2021 - Day 1

Catch up on all of the latest updates from day 1 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021 including presentations from Wave, Roche and Triplet.

Dr Rachel Harding, Dr Leora Fox, and Dr Jeff CarrollApril 28, 2021

Huntington's disease therapeutics conference 2021 - Day 2

Huntington's disease therapeutics conference 2021 - Day 2

Catch up on all of the latest updates from day 2 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021

Dr Rachel Harding, Dr Leora Fox, Dr Jeff Carroll, and Professor Ed WildApril 28, 2021

Huntington’s disease clinical trial round up

Huntington’s disease clinical trial round up

Catch up on all the latest Huntington's disease clinical trial news in this one stop shop article covering all of the recent developments in making medicines for Huntington's disease

Dr Rachel HardingApril 26, 2021

Good news from uniQure: gene therapy trial on track, and promising data in animals

Good news from uniQure: gene therapy trial on track, and promising data in animals

The first group of 10 participants have been dosed in uniQure’s clinical trial of an HD gene therapy, and three new manuscripts describe safe, widespread huntingtin lowering in animals.

Dr Leora FoxApril 15, 2021

Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials

Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials

Wave Life Sciences shared the disappointing news that their two ASOs in Phase 1/2 trials in HD patients did not successfully lower mutant huntingtin.

Dr Rachel Harding and Dr Leora FoxMarch 30, 2021

Sad News from Roche and Ionis - ASO Trial Halted Early

Sad News from Roche and Ionis - ASO Trial Halted Early

Disappointing news from Roche and Ionis; the phase III Tominersen huntingtin-lowering trial has been halted early

Dr Jeff Carroll and Dr Rachel HardingMarch 23, 2021

Vaccines and HD

Vaccines and HD

Many HD families have questions about vaccination for the coronavirus - RNA sounds scary! HDBuzz helps unpack the headlines about vaccine safety and HD.

Dr Jeff Carroll and Dr Rachel HardingFebruary 25, 2021

GPR52: Exploring a new way to lower huntingtin

GPR52: Exploring a new way to lower huntingtin

A Chinese research team developed a new way to lower huntingtin protein indirectly, by targeting a protein called GPR52. The molecules they designed were protective in cells and in mice with HD.

Dr Rachel HardingFebruary 11, 2021

Updates from the EHDN Plenary Meeting 2020

Updates from the EHDN Plenary Meeting 2020

Read our summary of the latest updates from the EHDN Plenary Meeting 2020

Dr Rachel HardingJanuary 08, 2021

Uncovering the dark side of DNA repair to design HD treatments

Uncovering the dark side of DNA repair to design HD treatments

A gene called MSH3 helps to repair our DNA, but in HD it can slip up and cause CAG repeats to lengthen. Researchers have uncovered new information about how MSH3 activity is controlled, opening the door to new therapeutic avenues.

Emma BuntingDecember 22, 2020